[
  {
    "quarter": "2021_Q2",
    "analyst_name": "Joanne Wunsch",
    "analyst_name_GT": "Joanne Wunsch",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "subtle market position",
    "quoted_compliment_GT": "Hi, can you hear me okay? Excellent. Good morning, and thank you for taking the question. It looked to us like when we compared the delivery versus consensus, there's two areas that might be lagging a little bit, our EP and CRM. But I also remember that there are a number of key products in those sections. Can you highlight one or two that might bring you back into sort of the market taker or gain position? Thank you. And my second question also is product-related. If I had to say to you what are the three products you want us to focus on over the next six to 12 months, what would your answer be? Thank you so much. ____ Hi, can you hear me okay?",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q2",
    "analyst_name": "Travis Steed",
    "analyst_name_GT": "Travis Steed",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "appreciate some of the longer-term comments you gave",
    "quoted_compliment_GT": "Hi. Good morning. Thanks for the question. I appreciate some of the longer-term comments you gave on operating margins. Just curious what the base we should be using for that 50%. our 50 basis points of margin expansion per year, if we should think about that 26% in the back half here. So thinking about the street somewhere in 26 and a half percent, next year would be a reasonable place to be at this point. Okay, great. Thank you. ____ Hi. Good morning. Thanks for the question.",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q3",
    "analyst_name": "Robbie Marcus",
    "analyst_name_GT": "Robbie Marcus",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "The growth in Watchman was excellent",
    "quoted_compliment_GT": "Yeah, great. Thanks for taking the questions. So maybe shifting over to some of the businesses, we'd love to get a sense of what you're seeing out in the field. I know it's early, but you have some competition coming from Watchmen. We'd love to hear what you're seeing there and just how you feel about your positioning and you know, how we should be thinking about trialing of competitive products in the near term. Great. Thanks for taking the questions.____",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q3",
    "analyst_name": "Vijay Kumar",
    "analyst_name_GT": "Vijay Kumar",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "I made a few comments before that, first of all, Watchman, the clinical results for Watchman Flex are extraordinarily good",
    "quoted_compliment_GT": "Hey, guys. Thanks for taking my question. I had two, one on Watchman and one on the tax rate, and I'll ask them both up front. Mike, on Watchman, we understand the market is underpenetrated and should expand massively given the amount of clinical data. But in the context of staffing challenges, you know, uh, code and my understanding is there are limited number of centers who can do these kinds of structural hard procedures. Um, you know, how should we think about market expansion versus, uh, uh, you know, is that going to accelerate in the, in this current environment, uh, given the challenges and you have a second player coming in, uh, would love your thoughts on, uh, on market expansion versus, uh, uh, competition and on, on tax, uh, Dan, Is the call for tax reform, what kind of impact should we assume? Thank you. Thanks, guys.____",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q3",
    "analyst_name": "Danielle Antofi",
    "analyst_name_GT": "Danielle Antofi",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "There's no doubt about it",
    "quoted_compliment_GT": "Hey, good morning, everyone. Thank you so much for taking the question. Mike, I appreciate all the commentary on COVID and improving, and I think we're all in the same boat. We hope it's better heading into next year. But just the new dynamic here is the hospital labor shortage, and I'm just curious sort of how you as a company are helping hospitals manage through that, what you're seeing hospitals do to adapt to be able to continue to get patients through the system and treated, given the labor shortages, which, you know, that to me seems like a tougher nut to crack as far as like sort of when that will resolve. It feels like that's not something that can sort of fix itself overnight. So we just love some commentary there. That's it for me. That was very helpful. Thank you.____",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q3",
    "analyst_name": "Anthony Petroni",
    "analyst_name_GT": "Anthony Petroni",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "And the short answer is it varies by business, right?",
    "quoted_compliment_GT": "Thanks. I'll have a two-part question. One's high level and one's on Watchman. High level, I guess, can you recap, and the company did a good job in the midst of the pandemic, what percent of the overall portfolio is linked to non-urgent elective procedures versus critical. And so maybe another way of asking when we look into 22, you know, what percent of the business could potentially see a tailwind, what potentially can face a headwind. And then on Watchman, maybe just high level on how we see shares trending over time. Is this, you know, potentially a 70% Boston market, 30% Abbott? And that takes into consideration the different designs out of the gate. Just curious to hear comments on the differences in targeting different size anatomies and potentially the limitation from competition in having a complete left appendage closure immediately post-surgery. Is that limiting for any follow-up surgeries? Thanks. Fair enough. Thanks.",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q4",
    "analyst_name": "Larry Beagleson",
    "analyst_name_GT": "Larry Beagleson",
    "level": 0,
    "level_GT": 1,
    "quoted_compliment": "",
    "quoted_compliment_GT": "Good morning. Thanks for taking the question and congrats on a nice finish to the year. Just on Watchman. Yeah, of course. Just on Watchman, just what you've seen so far with Amulet, you know, Boston, I mean, I'm sorry, Habit claims they had about 10% share in the U.S. in December. What are you assuming in the guidance, you know, for Watchman growth in 2022? And, you know, how confident are you you'll get the DAP label in the first half of this year? Thanks for taking the question. Thanks so much. ____ Congrats on a nice finish to the year",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q2",
    "analyst_name": "Rick Wise",
    "analyst_name_GT": "Rick Wise",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Thanks for taking the questions",
    "quoted_compliment_GT": "Good morning, Mike. Hi, Dan. Maybe you could give us a little more color on two key products, both Watchman and Faribault. Watchman, you did face a difficult 2Q comp, another excellent quarter. Maybe talk about where we are in the flex rollout and what's driving that growth and how sustainable you see it or what sustains this kind of impressive growth going ahead. And on FerriPulse, we recently checked in with some early FerriPulse adopters in Europe, and they love the technology, but were concerned about price and sort of limiting their utilization. So maybe you can sort of Talk about that, how you're addressing that issue, and any color on where you are with the number of accounts and your goals in terms of account opening in Europe. Any extra color would be great. Thank you so much. ____ Good morning, Mike. Hi, Dan. Maybe you could give us a little more color on two key products, both Watchman and Faribault.",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q2",
    "analyst_name": "Richard Newiter",
    "analyst_name_GT": "Richard Newiter",
    "level": 0,
    "level_GT": 1,
    "quoted_compliment": "",
    "quoted_compliment_GT": "Hi. Thanks for taking the questions and congrats on the quarter. You have some competitors out there that are calling out pricing strategies, particularly to head into 2023. Anything you'd call out there potentially as a lever to offset margin headwinds or sustain? And then also, if you could just comment a little bit more on the double-digit growth comment in the back half that you're expecting out of your Neuromod business? Any specific regions driving that? I'm assuming that doesn't assume a major pickup in SES, but other product categories, but please correct that if that's wrong. Thank you. ____ Hi. Thanks for taking the questions and congrats on the quarter.",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q3",
    "analyst_name": "Matt Taylor",
    "analyst_name_GT": "Matt Taylor",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "congrats to Dr. Meredith.",
    "quoted_compliment_GT": "Hi, thanks for taking the question. Can you hear me okay? Great. Can I ask one follow-up? I just wanted to know, you heard more about pent-up demand signs from some of the other peers that have reported. Would you espouse that? Are you seeing signs of that start to come due? And how do you square that, I guess, with â€“ with staffing getting slightly better? What are the things that I guess could release over the next couple quarters to help with the volumes? ____ ''",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q4",
    "analyst_name": "Joanne Lynch",
    "analyst_name_GT": "Joanne Lynch",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "congrats on a solid double-digit grower",
    "quoted_compliment_GT": "Thank you very much for taking the question, and good morning. I want to spend just a minute or two on urology and pelvic health business. I mean, that was a another 12% this quarter, 12.7% organically last quarter. What is driving that, and should we think of this more as a solid double-digit grower as we look forward? And my follow-up question, I'm going to just put it out there now, 50 basis points of operating margin expansion, or at least 50 basis points this year, where is that coming from? Thank you.____Thank you.",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q4",
    "analyst_name": "Vijay Kumar",
    "analyst_name_GT": "Vijay Kumar",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "just some cleanup questions here on the guidance assumptions",
    "quoted_compliment_GT": "Hey, guys. Thanks for taking my question. Just some cleanup questions here on the guidance assumptions. Mike, the 68% organic, it is what it is, but can you just remind us, you know, what are the incremental tailwinds, positive tailwinds here in 23 and any incremental headwinds versus 22? You know, some things I can think of, the FaroPulse becomes organic, maybe China has a little bit of headwind, but can you just go through some of those drivers? And Dan, on, you know, share count up, you know, 20 million, that seems egregious just given how we've seen share count progress throughout the year. I'm curious why and what's behind the share count assumptions of the year.____That's helpful, yes.",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q4",
    "analyst_name": "Cecilia Furlong",
    "analyst_name_GT": "Cecilia Furlong",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "thank you for taking the question",
    "quoted_compliment_GT": "Great. Good morning, and thank you for taking the question. I wanted to ask on Watchman. Specifically, what's underlying the double-digit growth outlook that you called out for 23? How are you thinking about market growth as well as Japan and China contributions? And then just a quick follow-up on AccurateNEO2 with the Prime XL registry. How are you thinking about approval timelines at this point in the U.S.?____Thank you for taking the questions.",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q1",
    "analyst_name": "Joanne Wench",
    "analyst_name_GT": "Joanne Wench",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "congrats on a really strong quarter",
    "quoted_compliment_GT": "Good morning, and may I reiterate or repeat the quarter? One of the things I've been trying to figure out this particular quarter is how much of what we're seeing is easy comps, pent-up demand, or something else. I know you can't particularly pick that apart on this kind of delivery, but if it is pent-up demand, is there any way to quantify how many quarters or what kind of tailwind that is And I'll throw my second question in, too. Fairpole seems to be doing quite well outside the United States, and we're getting a lot of questions on the timing of it in the United States and what that ramp may look like. If there's any color or sort of level setting of expectations, that would be appreciated. Thank you. Thank you so much. ____ Thank you so much.",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q1",
    "analyst_name": "Matt Taylor",
    "analyst_name_GT": "Matt Taylor",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "so, great result",
    "quoted_compliment_GT": "Good morning. Thanks for taking the question. So, great result. I guess what I'm struggling to understand is, you know, obviously you saw strong demand in the quarter, and I think we're seeing a lot of macro things improving, like staffing, et cetera. I mean, couldn't it actually theoretically get better sequentially? Why are we thinking so conservatively? Do you think that the direction of travel could be positive, negative, or neutral? And what are some of the background thoughts that you would base that on? Yeah, and then, Mike, just to follow up on that, I mean, thinking ahead to 2024, you know, if we do have some, let's call it supernormal growth this year, some catch-up or whatever, do you still think that you can grow in kind of the LRP range in 2024 over, you know, what could be a tough comp in 2023 if things play out well? Okay. I'll be there. Thanks, Ken. ____ Good morning.",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q3",
    "analyst_name": "Matthew O'Brien",
    "analyst_name_GT": "Matthew O'Brien",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "thanks for squeezing me in here",
    "quoted_compliment_GT": "Morning, thanks for squeezing me in here. I know you guys are a domestic company, but the performance in EMEA and APAC specifically were notable, and specifically APAC was really, really strong this quarter. Can you just give us a little more sense for, because I think those two collectively were roughly after growth this quarter. The durability of the performance in those geographies, is it a function of just more and more products into those areas? And so, you know, that's pretty straightforward. Or is it share taking that's required or what's really required to continue to deliver? Maybe not this level of growth, which is really strong again, but a very strong growth going forward where that's, you know, a significant contributor to the top line for 24, 25 and beyond. Thanks.____",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q4",
    "analyst_name": "Josh Jennings",
    "analyst_name_GT": "Josh Jennings",
    "level": 0,
    "level_GT": 1,
    "quoted_compliment": "",
    "quoted_compliment_GT": "Good morning. Thanks for taking the questions and congratulations for a strong end of the year. Wanted to ask about the international cardiac ablation market. Boston's incredible fourth quarter 40 plus percent growth. Thanks for taking the question.____Good morning. Thanks for taking the questions and congratulations for a strong end of the year.",
    "partial_name_match": false
  },
  {
    "quarter": "2024_Q2",
    "analyst_name": "Vijay Kumar",
    "analyst_name_GT": "Vijay Kumar",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "congratulations on my experience here",
    "quoted_compliment_GT": "Hi, guys. Thanks for taking my question, and my congratulations on my experience here. I had one question on USPFA, the 220% growth. Can you parse out what was the capital contribution versus, you know, capital contribution in the U.S. number? And I think you mentioned a TPT, you know, in the U.S., in the allocation setting. Any update on has Boston submitted its TPT? Thank you.____Hi, guys. Thanks for taking my question, and my congratulations on my experience here.",
    "partial_name_match": false
  },
  {
    "quarter": "2024_Q3",
    "analyst_name": "Joanne Lynch",
    "analyst_name_GT": "Joanne Lynch",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "thank you for the question",
    "quoted_compliment_GT": "Good morning, and thank you for the question. I want to talk about the amazing results of Faribault that we just saw, and specifically how you're thinking about moving, I was really interested in one quote that you said, to exceed 40 to 60% of global AF procedures by 2026. Thank you.____amazing results of Faribault",
    "partial_name_match": false
  }
]